NCT05333458View on ClinicalTrials.gov

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2027

Conditions
Advanced Alveolar Soft Part SarcomaAdvanced Soft Tissue SarcomaMetastatic Alveolar Soft Part SarcomaRefractory Alveolar Soft Part SarcomaUnresectable Alveolar Soft Part Sarcoma
Interventions
BIOLOGICAL

Atezolizumab

Given IV

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Selinexor

Given PO

Trial Locations (13)

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20007

RECRUITING

MedStar Georgetown University Hospital, Washington D.C.

20892

RECRUITING

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

ACTIVE_NOT_RECRUITING

National Institutes of Health Clinical Center, Bethesda

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

77030

RECRUITING

M D Anderson Cancer Center, Houston

90020

RECRUITING

Keck Medicine of USC Koreatown, Los Angeles

90033

RECRUITING

Los Angeles General Medical Center, Los Angeles

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

06105

RECRUITING

Smilow Cancer Hospital Care Center at Saint Francis, Hartford

06520

RECRUITING

Yale University, New Haven

06611

RECRUITING

Smilow Cancer Hospital Care Center-Trumbull, Trumbull

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH